Targeted neurostimulation reverses a spatiotemporal biomarker of treatment-resistant depression

Proc Natl Acad Sci U S A. 2023 May 23;120(21):e2218958120. doi: 10.1073/pnas.2218958120. Epub 2023 May 15.

Abstract

Major depressive disorder (MDD) is widely hypothesized to result from disordered communication across brain-wide networks. Yet, prior resting-state-functional MRI (rs-fMRI) studies of MDD have studied zero-lag temporal synchrony (functional connectivity) in brain activity absent directional information. We utilize the recent discovery of stereotyped brain-wide directed signaling patterns in humans to investigate the relationship between directed rs-fMRI activity, MDD, and treatment response to FDA-approved neurostimulation paradigm termed Stanford neuromodulation therapy (SNT). We find that SNT over the left dorsolateral prefrontal cortex (DLPFC) induces directed signaling shifts in the left DLPFC and bilateral anterior cingulate cortex (ACC). Directional signaling shifts in the ACC, but not the DLPFC, predict improvement in depression symptoms, and moreover, pretreatment ACC signaling predicts both depression severity and the likelihood of SNT treatment response. Taken together, our findings suggest that ACC-based directed signaling patterns in rs-fMRI are a potential biomarker of MDD.

Keywords: brain stimulation; depression; functional MRI.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Brain / diagnostic imaging
  • Depression
  • Depressive Disorder, Major* / diagnostic imaging
  • Depressive Disorder, Major* / therapy
  • Gyrus Cinguli / diagnostic imaging
  • Humans
  • Magnetic Resonance Imaging
  • Prefrontal Cortex / diagnostic imaging